Precision Medicine for <i>BRCA</i>/<i>PALB2</i>-Mutated Pancreatic Cancer and Emerging Strategies to Improve Therapeutic Responses to PARP Inhibition.

Principe, Daniel R

Precision Medicine for BRCA/PALB2-Mutated Pancreatic Cancer and Emerging Strategies to Improve Therapeutic Responses to PARP Inhibition.

Principe, Daniel R.

Afiliación

Principe DR; Medical Scientist Training Program, University of Illinois College of Medicine, Chicago, IL 60612, USA.

Cancers (Basel) ; 14(4)2022 Feb 11.

Article en En | MEDLINE | ID: mdl-35205643

Palabras clave

BRCA; PALB2; PARP inhibitor; homologous recombination deficiency; pancreatic ductal adenocarcinoma; precision medicine

Texto completo

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8869830
https://dx.doi.org/10.3390/cancers14040897

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Colección: 01-internacional Idioma: En Revista: Cancers (Basel) Año: 2022 Tipo del documento: Article País de afiliación: Estados Unidos

Texto completo

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8869830
https://dx.doi.org/10.3390/cancers14040897

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Colección: 01-internacional Idioma: En Revista: Cancers (Basel) Año: 2022 Tipo del documento: Article País de afiliación: Estados Unidos